Fujirebio Launches the Fully Automated Lumipulse ® G GFAP Assay for Research Use Only and Further Strengthens its Neuro Test Menu
H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G GFAP assay for the fully automated, random-access LUMIPULSE® G immunoassay systems. The Research Use Only (RUO) assay is now available in the United States, and it will be available in Japan, Europe and other regions* as of September this year. The Chemiluminescent Enzyme Immunoassay (CLEIA) test allows for the quantitative measurement of glial fibrillary acidic protein (GFAP) in human plasma and serum in just 35 minutes.
“In 2023 we already introduced two new important neuro assays for RUO-based detection of Neurofilament Light (NfL) and pTau 217,” said Goki Ishikawa, President and CEO of Fujirebio Holdings, Inc. “We continue our engagement in biomarker-based testing for neurological diseases with the Lumipulse G GFAP, affirming our commitment to play an essential partnering role in both research and clinical routine.”
The Lumipulse G GFAP assay will allow the scientific community and clinical research professionals to further study and understand the potential clinical utility of this promising astrocytic biomarker for neurological conditions such as multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, and brain-related acute traumatic injuries or stroke.1
With the fully automated random-access LUMIPULSE G platform, professionals will be able to measure GFAP in a user-friendly and reliable way. This standardized immunoassay platform is already widely available in labs for routine and research testing of neurological disease-related biomarkers. The new assay meets the necessary quality, throughput, and regulatory requirements to support potential routine testing of GFAP in combination with other tests from the Fujirebio neuro biomarker menu.
About Fujirebio
Fujirebio, a member of H.U. Group Holdings Inc., is a global leader in high-quality in vitro diagnostics (IVD) testing with more than 50 years’ accumulated experience in the research, development, production and worldwide commercialization of robust IVD products.
Fujirebio was the first company to develop and market cerebrospinal fluid (CSF) biomarkers under the Innogenetics brand over 25 years ago. Fujirebio offers a comprehensive line-up of manual and fully automated assays for neurological diseases and consistently partners with organizations and clinical experts across the world to develop new pathways for earlier, easier and more complete neurodegenerative diagnostic tools. More information can be found at www.fujirebio.com/neuro.
References:
- Abdelhak, A., Foschi, M., Abu-Rumeileh, S. et al. Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat Rev Neurol 18, 158–172 (2022). https://doi.org/10.1038/s41582-021-00616-3
* Please contact your local Fujirebio representative for the availability of this product in your country
Lumipulse is a registered trademark of Fujirebio Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240726266467/en/
Contacts
For media:
Public Relations Section, Public Relations/Sustainability Department,
H.U. Group Holdings, Inc..
Phone: +81-3-6279-0884
E-mail: pr@hugp.com
For investors and analysts:
IR/SR Dept.
Phone: +81-3-5909-3337
E-mail: ir@hugp.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AMGTA Gathers at Member Summit to Champion Sustainable Additive Manufacturing29.4.2025 13:00:00 CEST | Press Release
The Additive Manufacturer Green Trade Association (AMGTA), a global trade group focused on promoting sustainable and resource efficient manufacturing through 3D-printing and related additive manufacturing (AM) technologies held its 2025 Annual Member Summit April 7th at The Shinola Hotel in Detroit. Over 80 delegates from around the globe attended and contributed to the sharing of practices and technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425092570/en/ Attendees heard from keynote speaker Rich Voorberg, President of Siemens Energy North America, on how additive manufacturing capabilities are transforming spare part inventories, refurbishment and maintenance, and creating bottom-line value through streamlined supply chains. AMGTA Executive Director Sherri Monroe engaged Dr. Dean Bartles, President and CEO of Manufacturing Technology Deployment Group, in a one-on-one discussion of the state of advanced and a
Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities29.4.2025 12:30:00 CEST | Press Release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into a strategic collaboration with HealthPort, a multi-site comprehensive community health organization. HealthPort employs an integrated model centered around social determinants of health and this collaboration will help inform the potential delivery of COMP360 synthesized psilocybin treatment in underserved communities, if FDA approved. This agreement with HealthPort expands the set of collaborations that Compass has established representing a broad spectrum of settings where people living with treatment resistant depression (TRD) receive their care in the United States. HealthPort offers an integrated model of care aimed at helping those with behavioral health conditions and people impacted by poverty, disability and trauma. HealthPort is an evidence-based practice supporting thirteen dimensions of social determinants of
Cubic³ Research Finds Automotive OEMs View Connectivity as Crucial for Security as Half of Consumers Worry Their Car Can Be Hacked29.4.2025 11:45:00 CEST | Press Release
Research from Cubic³, a global leader in software-defined vehicle (SDV) solutions, emphasises the opportunities and challenges facing automotive OEMs as they persuade drivers to buy and subscribe to in-vehicle digital services, such as predictive maintenance, safety features and autonomous driving. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250429601913/en/ Boston Consulting Group forecasts the software-defined vehicle (SDV) market will create over $650 billion value potential by 2030. The survey of 8,000 consumers (equally split between the US, UK, Germany and Japan) and 60 global OEM executives finds that the challenge for OEMs is how to persuade and prove to drivers the benefits of paying for digital services, which constitute an integral part of SDVs and thereby turning this forecast into reality. Perceptions of Paying for Digital Services The research shows current consumer willingness to pay for in-car digital subs
Tecnotree Continues to Deliver Stable Q1 2025 Performance With Improved Free Cash Flow and Strategic Market Expansion29.4.2025 10:59:00 CEST | Press Release
Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, today announced its financial results for the first quarter of 2025, demonstrating resilient financial performance with significant improvement in free cash flow and strategic progress in market diversification. Q1 Results Net sales of EUR 16.9 million (16.3) +3.7% Year on Year, in constant currency, EUR 17.1 million, +4.6% Year on Year. Operating profit of EUR 4.5 million (4.4) +2.3% Year on Year. Operating margin of 26.9% (27.2%). Foreign exchange losses reduced to EUR 1.4 million (1.7). Net income EUR 1.5 million (1.6) -5.6% Year on Year. Gross cash flow from operations EUR 6.4 million (1.0). Positive free cash flow of EUR 1.0 million (-4.7). Earnings per share EUR 0.1 (0.1). Order book at the end of the period EUR 70.3 million (74.8). Tecnotree recorded a consistent cashflow performance, supported by enhanced collections and disciplined cost management. DSO (Days Sales Outstanding) r
Technology Reply Optimizes Pusterla 1880’s Quotation Management with Oracle AI Capabilities, Reducing the Estimation Time by 90%29.4.2025 10:00:00 CEST | Press Release
Technology Reply, the Reply Group company specialising in designing solutions based on Oracle technologies, today announced the development of an AI-based solution for managing the quotation process at Pusterla 1880. The implementation has reduced the time required to create new quotations to under five minutes and decreased the time needed to generate and validate cost estimates by 90%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250429596543/en/ “Leveraging the AI capabilities offered by Oracle Cloud Infrastructure and Oracle Database 23ai, and supported by Technology Reply’s expertise, we have significantly streamlined our quotation process. This has enabled us to respond more quickly to customer requests while reducing the risk of errors in our decision-making,” said Luca Meana, President, Pusterla 1880. Pusterla 1880, a company with over 140 years of experience in luxury packaging production, faced increasing complex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom